Acutaas Chemicals Ltd
NSE:ACUTAAS
Acutaas Chemicals Ltd
Acutaas Chemicals Ltd. engages in the development and commercialization of pharmaceutical intermediate products and specialty chemicals. The company is headquartered in Surat, Gujarat. The company went IPO on 2021-09-14. The company is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE) and other specialty chemicals for pharmaceuticals, agrochemicals, dyes, polymers, personal care, animal food, and other industries. The company manufactures pharma intermediates for certain active pharmaceutical ingredients (APIs), including dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban. The pharma intermediates cater to several therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. The company has developed and commercialized over 520 plus products, including specialty chemicals, Pharma Intermediates for APIs across 23 key therapeutic areas since inception and NCE across select high-growth high margin chronic therapeutic areas.
Acutaas Chemicals Ltd. engages in the development and commercialization of pharmaceutical intermediate products and specialty chemicals. The company is headquartered in Surat, Gujarat. The company went IPO on 2021-09-14. The company is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE) and other specialty chemicals for pharmaceuticals, agrochemicals, dyes, polymers, personal care, animal food, and other industries. The company manufactures pharma intermediates for certain active pharmaceutical ingredients (APIs), including dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban. The pharma intermediates cater to several therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. The company has developed and commercialized over 520 plus products, including specialty chemicals, Pharma Intermediates for APIs across 23 key therapeutic areas since inception and NCE across select high-growth high margin chronic therapeutic areas.
Revenue Growth: Acutaas Chemicals delivered strong Q3 results with revenue reaching INR 393.2 crores, up 43% year-on-year.
Profit & Margins: Profit after tax crossed INR 100 crore for the quarter, with gross margin expanding to a record 57% and EBITDA margin rising to 38.3%.
Upgraded Guidance: Management raised FY '26 revenue growth guidance from 25% to about 30% and increased full-year EBITDA margin guidance to 32–35%.
Business Diversification: The company is making progress in pharmaceutical intermediates, battery chemicals (new block inaugurated), and semiconductor chemicals (JV CapEx on track), aiming for all three to be growth engines by FY 2028.
CDMO Pipeline: Four CDMO products validated and expected to contribute meaningfully from FY '27; INR 1,000 crore CDMO revenue targeted by FY '28.
Capital Expenditure: FY '26 CapEx revised to around INR 220 crores (down from INR 250 crores), plus INR 130 crores invested in the Indichem JV so far.
Operational Efficiency: Margin gains driven by improved product mix and operational improvements, including energy savings from a solar plant.
